Rapid Bioassay for Detection of Thyroid-Stimulating Antibodies Using Cyclic Adenosine Monophosphate-Gated Calcium Channel and Aequorin

Background: Thyroid-stimulating antibodies (TSAb) are known to be responsible for hyperthyroidism in Graves' disease (GD). The conventional methods to measure TSAb depend on cell-based assays that require cumbersome procedures and a sterilized tissue culture technique. The aim of the present study was to develop a ready-to-use cell-based assay for measuring TSAb activity without requiring sterilized conditions. Methods: We developed a new assay kit using a frozen Chinese hamster ovary cell line expressing the thyroid-stimulating hormone receptor, cyclic adenosine monophosphate (cAMP)-gated calcium channel and aequorin, tentatively named the aequorin TSAb assay. Activated stimulatory G-protein-coupled adenylate cyclase increases intracellular cAMP, which then binds to the cyclic nucleotide-gated calcium channel. Activation of this channel allows Ca2+ to enter the cell, and the influx of Ca2+ can be measured with aequorin, which is quantified by a luminometer. Results can be obtained in only 4 h without sterilized conditions. TSAb activities were expressed by international units using the NIBSC 08/204 standard. Results: Positive results of aequorin TSAb were obtained in 197 of 199 (98.9%) of untreated patients with GD. Only 1 of 42 (2.3%) patients with painless thyroiditis had a weakly positive aequorin TSAb. All 45 patients with subacute thyroiditis and 185 normal subjects showed negative aequorin TSAb. As for chronic thyroiditis, all 52 euthyroid patients showed negative aequorin TSAb, but 8 of 50 (16.0%) hypothyroid patients had a positive reaction. However, these positive reactions were not induced by serum thyroid-stimulating hormone (TSH) and were thought to be induced by the stimulating activity of anti-TSH receptor immunoglobulins. Conventional porcine TSAb and Elecsys thyroid-stimulating hormone receptor antibodies were positive in 69.3 and 95.5% of GD, respectively. Conclusion: The aequorin TSAb assay was positive in 98.9% of GD and was more sensitive than the conventional assay. This assay can be conducted in only 4 h without sterilized conditions and is practically useful in general clinical laboratories.

[1]  A. Miyauchi,et al.  Differentiation of postpartum Graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow. , 2014, Thyroid : official journal of the American Thyroid Association.

[2]  B. Rapoport,et al.  Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. , 2013, Thyroid : official journal of the American Thyroid Association.

[3]  P. Vitti,et al.  A TSHr-LH/CGr chimera that measures functional TSAb in Graves' disease. , 2012, The Journal of clinical endocrinology and metabolism.

[4]  G. Kahaly,et al.  Bioassays for TSH-receptor autoantibodies: an update. , 2010, Autoimmunity reviews.

[5]  G. Kahaly,et al.  A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. , 2010, The Journal of clinical endocrinology and metabolism.

[6]  A. Miyauchi,et al.  Evaluation of a new rapid and fully automated electrochemiluminescence immunoassay for thyrotropin receptor autoantibodies. , 2008, Thyroid : official journal of the American Thyroid Association.

[7]  A. Mithöfer,et al.  Aequorin-based measurements of intracellular Ca2+-signatures in plant cells , 2002, Biological Procedures Online.

[8]  N. Morgenthaler,et al.  Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites. , 2007, The Journal of clinical endocrinology and metabolism.

[9]  D. Weightman,et al.  A new assay for thyrotropin receptor autoantibodies. , 2004, Thyroid : official journal of the American Thyroid Association.

[10]  T. Pozzan,et al.  Intracellular targeting of the photoprotein aequorin: A new approach for measuring, in living cells, Ca2+ concentrations in defined cellular compartments , 2004, Cytotechnology.

[11]  M. Detheux,et al.  Aequorin-based functional assays for G-protein-coupled receptors, ion channels, and tyrosine kinase receptors. , 2002, Receptors & channels.

[12]  A. Nagata,et al.  Clinical significance of a sensitive assay for thyroid-stimulating antibodies in Graves' disease using polyethylene glycol at high concentrations and porcine thyroid cells. , 1999, Endocrine journal.

[13]  N. Morgenthaler,et al.  Development of a luminescent bioassay for thyroid stimulating antibodies. , 1999, The Journal of clinical endocrinology and metabolism.

[14]  Watson,et al.  A new chemiluminescent assay for the rapid detection of thyroid stimulating antibodies in Graves' disease , 1998, Clinical endocrinology.

[15]  N. Amino,et al.  Subtypes of anti-TSH receptor antibodies classified by various assays using CHO cells expressing wild-type or chimeric human TSH receptor. , 1997, Thyroid : official journal of the American Thyroid Association.

[16]  M. L. Ruiz,et al.  Cloning and characterization of an olfactory cyclic nucleotide-gated channel expressed in mouse heart. , 1996, Journal of molecular and cellular cardiology.

[17]  B. Rapoport,et al.  Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. , 1989, Biochemical and biophysical research communications.

[18]  K. Ichihara,et al.  EVALUATION OF TSH RECEPTOR ANTIBODY BY ‘NATURAL IN VIVO HUMAN ASSAY’ IN NEONATES BORN TO MOTHERS WITH GRAVES’ DISEASE , 1989, Clinical endocrinology.

[19]  Y. Iwatani,et al.  IN‐VITRO CONVERSION OF BLOCKING TYPE ANTI‐TSH RECEPTOR ANTIBODY TO THE STIMULATING TYPE BY ANTI‐HUMAN IgG ANTIBODIES , 1987, Clinical endocrinology.

[20]  P. Spiller,et al.  Blood flow. , 1985, European heart journal.